Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.42 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303924 | 0.86 | GRIN2B (0.52) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL7907489 | 0.85 | GRIN2B (0.45) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL26113929 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL30588458 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL12139719 | 0.82 | MTOR (0.53) | TRPC3TRPC7 | |
| SCHEMBL14794928 | 0.82 | MTOR (0.52) | — | |
| SCHEMBL11961137 | 0.80 | GRIN2B (0.40) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL3808612 | 0.80 | GRIN2B (0.54) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL55671 | 0.80 | PIK3CA (0.53) | NR3C1 | |
| SCHEMBL1128398 | 0.79 | NR3C1 (0.57) | CYP2C9CYP3A4MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | disclosed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | SMN1; SMN2 2950/4885NPC1 2162/4885RAB9A 498/4885 |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | MTOR, ULK1, ULK2 | SMN1; SMN2 2437/4885NPC1 1857/4885RAB9A 679/4885 |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | SMN1; SMN2 2950/4885NPC1 2162/4885RAB9A 498/4885 |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | SMN1; SMN2 2252/4885NPC1 2085/4885RAB9A 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.